Corbus Pharmaceuticals will conduct an underwritten registered public offering of its common stock, with Jefferies LLC and Piper Sandler & Co. serving as joint book‑running managers. The offering will include shares and, for certain investors, pre‑funded warrants to purchase common stock. The underwriters will receive a 30‑day option to purchase up to an additional 15% of the shares sold in the offering.
Proceeds from the offering will be used to fund the clinical development of Corbus’s oncology and obesity pipeline, including CRB‑701, CRB‑601, and CRB‑913, as well as for working capital and other general corporate purposes. The company’s oncology candidate CRB‑701 has received Fast Track designation from the FDA for head and neck squamous cell carcinoma and cervical cancer, and recent data presented at the European Society for Medical Oncology Congress have attracted increased analyst attention.
The registration statement for the offering became effective on March 20, 2024. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC. The securities are not qualified under any state blue‑sky laws and will be offered only through a prospectus.
In the fourth quarter of 2024, Corbus reported a net loss of $9.5 million, or $0.78 per diluted share, compared with a net loss of $8.0 million, or $1.81 per diluted share, in the fourth quarter of 2023. For the full year 2024, the company’s net loss was $40.2 million, or $3.68 per diluted share, versus a net loss of $44.6 million, or $10.31 per diluted share, in 2023. As of December 31, 2024, Corbus had $149.1 million in cash, cash equivalents, and investments, expected to fund operations through the third quarter of 2027. As of September 30, 2025, the company’s cash position was approximately $104.0 million.
Corbus previously completed a public offering in January 2024, raising roughly $82.2 million. The current offering is intended to strengthen the company’s financial position and support the advancement of its pipeline candidates in a highly competitive oncology and obesity market.
The company’s current ratio stands at 9.21, indicating a strong liquidity position. The new capital will provide additional resources for clinical trials, regulatory submissions, and potential future acquisitions or partnerships that could accelerate the development of its pipeline.
The offering is subject to market conditions, and there is no assurance that it will be completed or that the size or terms will be as proposed. The final terms will be determined at closing.
The securities will be offered only through a prospectus and are not qualified under any state blue‑sky laws.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.